Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Mansoor Husain(Ted Rogers Centre for Heart Research), Andreas L. Birkenfeld(Paul Langerhans Institute Dresden), Morten Donsmark(Novo Nordisk (Denmark)), Kathleen Dungan(The Ohio State University), Freddy G. Eliaschewitz(DASA (Brazil)), Denise Reis Franco(DASA (Brazil)), Ole Kleist Jeppesen(Novo Nordisk (Denmark)), Ildiko Lingvay(The University of Texas Southwestern Medical Center), Ofri Mosenzon(Hebrew University of Jerusalem), Sue D. Pedersen(LMC Diabetes & Endocrinology (Canada)), Cees J. Tack, Mette S. Thomsen(Novo Nordisk (Denmark)), Tina Vilsbøll(Steno Diabetes Centers), Mark Warren(Physicians East), Stephen C. Bain(Swansea University)
Cited by 1,887Open Access
Abstract
Establishing cardiovascular safety of new therapies for type 2 diabetes is important. Safety data are available for the subcutaneous form of the glucagon-like peptide-1 receptor agonist semaglutide but are needed for oral semaglutide.
Related Papers
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso, Gilbert H. Daniels, Kirstine Brown‐Frandsen et al.|New England Journal of Medicine|2016|7.3k